Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FULC Stock Forecast 2025-2026
$8.90
Current Price
$481.65M
Market Cap
Buy 7
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to FULC Price Targets
+124.7%
To High Target of $20.00
+68.5%
To Median Target of $15.00
-32.6%
To Low Target of $6.00
FULC Price Momentum
-18.6%
1 Week Change
+16.3%
1 Month Change
+123.1%
1 Year Change
+89.4%
Year-to-Date Change
-27.0%
From 52W High of $12.19
+284.4%
From 52W Low of $2.32
📊 TOP ANALYST CALLS
Did FULC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fulcrum is one of their latest high-conviction picks.
Latest FULC Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, FULC has a bullish consensus with a median price target of $15.00 (ranging from $6.00 to $20.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $8.90, the median forecast implies a 68.5% upside. This outlook is supported by 7 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Andrew Fein at HC Wainwright & Co., projecting a 124.7% upside. Conversely, the most conservative target is provided by Madhu Kumar at Goldman Sachs, suggesting a 32.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FULC Analyst Ratings
7
Buy
1
Hold
1
Sell
FULC Price Target Range
Low
$6.00
Average
$15.00
High
$20.00
Current: $8.90
Latest FULC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FULC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 24, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $18.00 |
| Nov 24, 2025 | Truist Securities | Gregory Renza | Buy | Initiates | $14.00 |
| Oct 30, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $7.00 |
| Oct 30, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $16.00 |
| Oct 20, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Reiterates | $12.00 |
| Jul 30, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $5.00 |
| Jul 29, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Upgrade | $12.00 |
| May 29, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $9.00 |
| May 23, 2025 | Leerink Partners | Joseph Schwartz | Outperform | Upgrade | $12.00 |
| May 15, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Upgrade | $10.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Andrew Fein | Neutral | Reiterates | $4.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Andrew Fein | Neutral | Reiterates | $4.00 |
| Nov 14, 2024 | RBC Capital | Gregory Renza | Sector Perform | Reiterates | $4.00 |
| Sep 13, 2024 | HC Wainwright & Co. | Andrew Fein | Neutral | Downgrade | $4.00 |
| Sep 13, 2024 | RBC Capital | Gregory Renza | Sector Perform | Downgrade | $4.00 |
| Sep 12, 2024 | Cantor Fitzgerald | Kristen Kluska | Neutral | Downgrade | $N/A |
| Sep 12, 2024 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $4.00 |
| Sep 12, 2024 | Stifel | Dae Gon Ha | Hold | Downgrade | $3.00 |
| Sep 12, 2024 | B of A Securities | Tazeen Ahmad | Underperform | Downgrade | $2.00 |
| Sep 9, 2024 | B of A Securities | Tazeen Ahmad | Neutral | Upgrade | $10.00 |
Fulcrum Therapeutics Inc. (FULC) Competitors
The following stocks are similar to Fulcrum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fulcrum Therapeutics Inc. (FULC) Financial Data
Fulcrum Therapeutics Inc. has a market capitalization of $481.65M with a P/E ratio of -55.6x. The company generates $80.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -24.8% and return on equity of -31.2%.
Valuation Metrics
Market Cap
$481.65M
Enterprise Value
$288.02M
P/E Ratio
-55.6x
PEG Ratio
4.9x
Price/Sales
6.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-24.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+41.7%
Current Ratio
17.7x
Debt/Equity
3.5x
ROE
-31.2%
ROA
-20.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fulcrum Therapeutics Inc. (FULC) Business Model
About Fulcrum Therapeutics Inc.
What They Do
Develops therapies for genetically defined diseases.
Business Model
Fulcrum Therapeutics generates revenue by developing and commercializing innovative therapies that target rare genetic disorders. The company focuses on gene regulation to create treatments aimed at specific conditions, such as fragile X syndrome and facioscapulohumeral muscular dystrophy, addressing significant unmet clinical needs in the healthcare market.
Additional Information
Founded in 2015 and based in Cambridge, Massachusetts, Fulcrum Therapeutics is positioned as a leader in precision medicine through its pioneering work in epigenetic modulation. The company's ongoing research initiatives underscore its commitment to transforming patient outcomes and advancing the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
45
CEO
Mr. Alexander C. Sapir
Country
United States
IPO Year
2019
Website
www.fulcrumtx.comFulcrum Therapeutics Inc. (FULC) Latest News & Analysis
Latest News
Quick Summary
Fulcrum Therapeutics (Nasdaq: FULC) will hold an investor event on December 7, 2025, at 7:00 a.m. to discuss its developments in small molecules for rare diseases.
Why It Matters
The investor event announcement signals potential updates on clinical progress or financial performance, which could influence Fulcrum Therapeutics' stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fulcrum Therapeutics granted non-statutory stock options to two new employees under its 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq regulations.
Why It Matters
The granting of stock options indicates Fulcrum's growth and commitment to attracting talent, potentially enhancing innovation and future profitability, which can influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pociredir Phase 1b PIONEER Trial data on sickle cell disease will be presented and published, focusing on 12 mg and 20 mg dosage cohorts.
Why It Matters
The presentation of Pociredir Phase 1b trial data for sickle cell disease may indicate the drug's potential efficacy, impacting future market prospects and investment decisions in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fulcrum Therapeutics, Inc. (FULC) will hold its Q3 2025 earnings call on October 29, 2025, at 8:00 AM EDT, featuring key executives and analysts from various financial institutions.
Why It Matters
Fulcrum Therapeutics' Q3 earnings call provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
1 month ago
Quick Summary
Fulcrum Therapeutics reported positive results from the 12 mg cohort of the PIONEER trial for sickle cell disease. Enrollment is complete for the 20 mg cohort, with data expected by year-end. The company has $200.6 million in cash, ensuring a runway into 2028.
Why It Matters
Positive trial results for pociredir in sickle cell disease and strong cash reserves suggest potential for further development and stability, which may enhance investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will release its Q3 2025 financial results on October 29, 2025, before market open, followed by a conference call at 8:00 a.m. ET.
Why It Matters
Fulcrum Therapeutics' upcoming financial results and corporate update could influence stock performance, signaling potential growth or challenges in their pipeline for rare diseases.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FULC Stock
What is Fulcrum Therapeutics Inc.'s (FULC) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Fulcrum Therapeutics Inc. (FULC) has a median price target of $15.00. The highest price target is $20.00 and the lowest is $6.00.
Is FULC stock a good investment in 2026?
According to current analyst ratings, FULC has 7 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $8.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FULC stock?
Wall Street analysts predict FULC stock could reach $15.00 in the next 12 months. This represents a 68.5% increase from the current price of $8.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fulcrum Therapeutics Inc.'s business model?
Fulcrum Therapeutics generates revenue by developing and commercializing innovative therapies that target rare genetic disorders. The company focuses on gene regulation to create treatments aimed at specific conditions, such as fragile X syndrome and facioscapulohumeral muscular dystrophy, addressing significant unmet clinical needs in the healthcare market.
What is the highest forecasted price for FULC Fulcrum Therapeutics Inc.?
The highest price target for FULC is $20.00 from Andrew Fein at HC Wainwright & Co., which represents a 124.7% increase from the current price of $8.90.
What is the lowest forecasted price for FULC Fulcrum Therapeutics Inc.?
The lowest price target for FULC is $6.00 from Madhu Kumar at Goldman Sachs, which represents a -32.6% decrease from the current price of $8.90.
What is the overall FULC consensus from analysts for Fulcrum Therapeutics Inc.?
The overall analyst consensus for FULC is bullish. Out of 16 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $15.00.
How accurate are FULC stock price projections?
Stock price projections, including those for Fulcrum Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 9:28 PM UTC